Syneos Health Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Syneos Health stock.
View analyst ratings for Syneos Health or view top-rated stocks.

9 Wall Street analysts have issued 12-month price objectives for Syneos Health's shares. Their SYNH stock forecasts range from $75.00 to $122.00. On average, they anticipate Syneos Health's share price to reach $98.78 in the next year. This suggests a possible upside of 35.3% from the stock's current price.
View analysts' price targets for Syneos Health or view top-rated stocks among Wall Street analysts.

Syneos Health's stock was trading at $102.68 at the beginning of the year. Since then, SYNH shares have decreased by 28.9% and is now trading at $73.01.
View the best growth stocks for 2022 here.

Syneos Health saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 1,910,000 shares, a drop of 16.2% from the May 15th total of 2,280,000 shares. Based on an average daily volume of 700,100 shares, the short-interest ratio is presently 2.7 days. Currently, 1.9% of the company's stock are sold short.
View Syneos Health's Short Interest.

Syneos Health is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Syneos Health.

Syneos Health, Inc. (NASDAQ:SYNH) released its earnings results on Friday, April, 29th. The company reported $0.89 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.05. The business earned $1.34 billion during the quarter, compared to analysts' expectations of $1.32 billion. Syneos Health had a trailing twelve-month return on equity of 13.33% and a net margin of 4.54%. The business's revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the business earned $0.66 earnings per share.
View Syneos Health's earnings history.

Syneos Health updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $5.05-$5.25 for the period, compared to the consensus estimate of $5.08. The company issued revenue guidance of $5.60 billion-$5.75 billion, compared to the consensus revenue estimate of $5.65 billion.

322 employees have rated Syneos Health CEO Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among Syneos Health's employees.

Some companies that are related to Syneos Health include ICON Public (ICLR), Incyte (INCY), Charles River Laboratories International (CRL), Bitcoin Group (BTGGF), Medpace (MEDP), National Research (NRC), SomaLogic (SLGC), MaxCyte (MXCT), Absci (ABSI), Avista Public Acquisition Corp. II (AHPA), Inotiv (NOTV), Science 37 (SNCE), Starpharma (SPHRY), Luna Innovations (LUNA) and Zymergen (ZY).
View all of SYNH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.24%), Vanguard Group Inc. (9.48%), Wellington Management Group LLP (9.19%), Clearbridge Investments LLC (3.80%), Massachusetts Financial Services Co. MA (2.80%) and State Street Corp (2.59%). Company insiders that own Syneos Health stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Healthcare of Ontario Pension Plan Trust Fund, Strs Ohio, Wellington Management Group LLP, Dana Investment Advisors Inc., GW&K Investment Management LLC, Russell Investments Group Ltd., and Envestnet Asset Management Inc.. Company insiders that have sold Syneos Health company stock in the last two years include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Thomas H Lee Advisors, Llc, and Tom Allen.
View insider buying and selling activity for Syneos Health or view top insider-selling stocks.

SYNH stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Massachusetts Financial Services Co. MA, Cooke & Bieler LP, Goldman Sachs Group Inc., Crestwood Advisors Group LLC, Clearbridge Investments LLC, Bank of America Corp DE, and Assenagon Asset Management S.A..
View insider buying and selling activity for Syneos Health or or view top insider-buying stocks.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYNH stock can currently be purchased for approximately $73.01.

Syneos Health (NASDAQ:SYNH) has a market capitalization of $7.49 billion and generates $5.21 billion in revenue each year. The company earns $234.83 million in net income (profit) each year or $2.31 on an earnings per share basis.

Syneos Health employs 28,000 workers across the globe.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The official website for Syneos Health is www.syneoshealth.com. The company can be reached via phone at (919) 876-9300, via email at [email protected], or via fax at 919-876-9360.